Table 2.

Mean zone of inhibition (mm) of different antibiotics, silver nanoparticles and combined antibiotics with silver nanoparticles.

Pathogens	Antibiotics (a)	SNP	Antibiotics + SNP (b)	Fold increase % [(b − a)/a] × 100
Kanamycin
B. subtilis	25	14	28	12
E. coli	24	13	27	12.5
S. aureus	23	17	25	8.6
K. pneumonae	12	11	15	25
				Overall synergistic antibacterial effect: 16%
Gentamicin
B. subtilis	32	12	33	3.1
E. coli	26	18	30	15.3
S. aureus	25	12	26	4.0
K. pneumonae	18	10	22	22
				Overall synergistic antibacterial effect: 11.15%
Streptomycin
B. subtilis	26	12	27	3.8
E. coli	25	13	30	20
S. aureus	21	15	23	9.5
K. pneumonae	28	10	30	7.1
				Overall synergistic antibacterial effect: 10%
Bacitracin
B. subtilis	–	13	15	100
E. coli	–	16	19	100
S. aureus	08	12	12	50
K. pneumonae	–	09	09	100
				Overall synergistic antibacterial effect: 87%
Chloromphenicol
B. subtilis	30	12	31	3.3
E. coli	30	14	32	6.6
S. aureus	25	14	29	16
K. pneumonae	17	09	19	11.7
				Overall synergistic antibacterial effect: 9.4%
Erythromycin
B. subtilis	34	10	37	8.8
E. coli	25	15	27	8.0
S. aureus	32	13	34	6.25
K. pneumonae	12	09	14	16.0
				Overall synergistic antibacterial effect: 9.7%